Harvard Bioscience Q3 Revenue Up 8% to $22.2M, Cuts EBITDA Outlook

Harvard Bioscience, Inc. (Nasdaq: HBIO) reported third quarter 2026 revenue of $22.2 million on 10 November 2026, an 8% increase from $20.6 million in the same quarter a year earlier, according to the company's earnings release. Net loss widened to $(2.6) million from $(1.2) million, while adjusted EBITDA slipped to $1.8 million from $2.0 million. The life-science tools maker reaffirmed full-year revenue growth guidance of 3% to 5% but trimmed its adjusted EBITDA target to between (1%) and 4% growth, citing a heavier mix of lower-margin products.

Context — why Harvard Bioscience's Q3 beat matters now

The quarter marks Harvard Bioscience's second consecutive period of year-over-year topline growth. The company reported 8% revenue growth in the third quarter, following what management described as a prior quarter of strong growth. That run follows a difficult 2025, when a $48.0 million goodwill impairment pushed the nine-month net loss to $(53.9) million.

The current nine-month net loss of $(9.0) million is roughly 83% narrower than the prior-year figure, a gap driven almost entirely by that non-cash charge rather than by operational improvement. Adjusted EBITDA for the nine months was $4.2 million, essentially flat against $4.3 million a year earlier, so the underlying earnings picture has not shifted much.

Chief Executive John Duke pointed to double-digit revenue growth to contract research organizations and customers in China, driven by organoids, respiratory, and fluidics products. He also said the company's revamped sales and marketing teams are delivering encouraging results and that Project Viking remains on track for completion by the end of the first quarter of 2027.

Cash generation flipped negative. Operations used $0.6 million over the nine months, against $6.8 million provided in the prior-year period. That swing, combined with a net debt position of $35.1 million, frames why the guidance revision carries more weight than the topline beat.

Data — what the numbers show

The gross margin line is where the quarter's tension sits. GAAP gross margin fell to 55.4% from 58.4% a year earlier, and adjusted gross margin dropped to 57.1% from 59.2%. Cost of revenues rose to $9.9 million from $8.6 million, outpacing the 7.8% revenue gain.

Metric	Q3 2026	Q3 2025
Revenue	$22.2M	$20.6M
GAAP gross margin	55.4%	58.4%
Adjusted gross margin	57.1%	59.2%
Net loss	$(2.6)M	$(1.2)M
Adjusted EBITDA	$1.8M	$2.0M
Cash from operations	$(0.2)M	$1.0M

Operating expenses climbed to $13.5 million from $11.8 million, with sales and marketing up to $5.4 million from $4.6 million and general and administrative costs up to $4.8 million from $4.2 million. Interest expense rose to $1.8 million from $1.3 million, reflecting the higher debt load.

On a constant-currency basis, third-quarter revenue growth was also 7.8%, so foreign exchange contributed a negligible drag of less than 1%. Over the nine months, however, currency added roughly 1.2 percentage points: reported growth of 4.6% versus 3.4% at constant currency.

The balance sheet shows cash of $4.9 million against total debt of $37.2 million, leaving net debt of $35.1 million, up from $27.5 million a year earlier. Stockholders' equity fell to $5.1 million from $13.7 million at year-end 2025.

Analysis — what it means for markets and sectors

The guidance cut is a mix problem, not a demand problem. Management attributed the lower adjusted EBITDA target to higher-than-expected sales of certain lower-margin CMT products and a greater revenue contribution from distribution channels and China. Both are volume-positive and margin-negative, which explains why revenue guidance held while profitability guidance fell.

The read-across for the broader life-science tools sector is that geographic and channel mix still carries more earnings risk than headline demand. Companies with heavy China exposure and distributor-led sales face the same arithmetic: revenue lands, but at a lower incremental margin than direct sales into Western academic and pharma accounts.

One limitation worth weighing: adjusted figures strip out $658,000 of restructuring-related charges in the quarter and $864,000 of non-GAAP restructuring adjustments, plus stock-based compensation and acquired asset amortization. On a GAAP basis the company posted an operating loss of $(1.2) million, versus operating income of $197,000 a year earlier. The gap between adjusted operating income of $1.2 million and the GAAP loss is the cost of the restructuring program.

Positioning reflects that ambiguity. The revenue beat supports the growth narrative, but negative operating cash flow and rising net debt give income-focused holders little to work with. Fourth-quarter guidance implies a sharp sequential step-up, which is where the burden of proof now sits.

Outlook — what to watch next

Harvard Bioscience guided fourth-quarter revenue to between $23.7 million and $25.5 million, adjusted gross margin to 59% to 61%, and adjusted EBITDA to $3.8 million to $4.2 million. Hitting the midpoint of that EBITDA range would require roughly double the third-quarter figure, with the company attributing the expected improvement to CMT and new product demand, sequential margin expansion, and better year-over-year profitability.

The full-year adjusted EBITDA target of (1%) to 4% growth is the number to track, because it now sits below the 3% to 5% revenue growth the company reaffirmed. Adjusted gross margin guidance of 57% to 59% for the year brackets the nine-month actual of 57.9%.

Project Viking's completion, targeted for the end of the first quarter of 2027, is the next structural catalyst. Whether the restructuring charges that have run through 2026 roll off cleanly will determine how closely adjusted and GAAP results converge. The company did not disclose the total cost or expected savings from that program.

Frequently Asked Questions

Why did Harvard Bioscience cut its 2026 adjusted EBITDA guidance?

The company said the revision accounts for higher-than-expected sales of certain lower-margin CMT products and a larger revenue contribution from distribution channels and China. Revenue guidance was reaffirmed at 3% to 5% growth, so the change reflects product and channel mix rather than weaker demand. Fourth-quarter adjusted EBITDA guidance of $3.8 million to $4.2 million implies a substantial sequential improvement from the $1.8 million reported in the third quarter.

What does the widening net loss mean for Harvard Bioscience shareholders?

The third-quarter net loss of $(2.6) million compared with $(1.2) million a year earlier, and diluted loss per share widened to $(0.58) from $(0.28). The nine-month loss narrowed sharply to $(9.0) million from $(53.9) million, but that improvement stems from a $48.0 million goodwill impairment recorded in the first quarter of 2025. Operating cash flow turned negative over the nine months, and net debt rose to $35.1 million.

What is Project Viking and when does it finish?

Project Viking is a restructuring and reorganization program referenced by Chief Executive John Duke, who said it remains on track for completion by the end of the first quarter of 2027. Restructuring-related charges tied to the effort totaled $658,000 in the third quarter and $1.2 million over the nine months, with additional non-GAAP restructuring adjustments of $864,000 and $1.5 million respectively. The company did not disclose the program's total cost or expected savings.

Bottom Line

Harvard Bioscience grew revenue 8% but cut full-year adjusted EBITDA guidance, so margin mix now outweighs the topline beat.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.